A securities class action lawsuit has been filed against Organon & Co. on behalf of investors who purchased the company's securities between October 31, 2024, and April 30, 2025. The lawsuit claims that Organon, following its $1.2 billion acquisition of Dermavant, assured investors that maintaining its dividend was its top capital allocation priority. However, it is alleged that the company shifted its focus to debt reduction instead. Investors have until July 22, 2025, to seek appointment as lead plaintiff in the case. Organon, headquartered in Jersey City, NJ, specializes in women's health.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。